Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 8, 2023, details a material definitive agreement entered into by Femasys Inc. on November 14, 2023. The filing covers a private placement of securities, changes to the Board of Directors, and a temporary compliance issue with NASDAQ listing rules regarding the Audit Committee.
Key Financial Metrics and Transaction Details
The filing does not report historical revenue, profit, or cash flow metrics. The primary financial event is a private placement with the following terms:
- Aggregate Gross Proceeds: $6,850,000.
- Senior Unsecured Convertible Notes: $6,850,000 principal amount; 6.00% annual interest; 2-year maturity; convertible at $1.18 per share.
- Series A Warrants: 5,805,083 shares; exercise price $1.18; 5-year term.
- Series B Warrants: 5,805,083 shares; exercise price $1.475; 1-year term.
- Use of Proceeds: General corporate purposes.
Material Changes and Corporate Governance
Significant changes to the company's governance structure and capitalization include:
- Board Resignations: Keith Kendall, Anne Morrissey, and Wendy Perrow resigned as directors effective November 8, 2023. Ms. Morrissey disagreed with the statement that her resignation was not due to a dispute with the Company.
- Board Expansion and Investor Rights: The Board size will be set to five directors. PharmaCyte (an investor) has the right to nominate one director until it owns less than 4.99% of outstanding shares or the Notes are repaid. Joshua Silverman (PharmaCyte interim CEO) is expected to be appointed to the Board.
- NASDAQ Compliance: The resignations temporarily reduced the Audit Committee below the required three members. Compliance was restored on November 9, 2023, by appointing Edward Uzialko to the committee and designating Charles Larsen as the financial expert.
- Collaboration Agreement: A joint research committee will be established with PharmaCyte to evaluate potential technology in-licenses or acquisitions.
Outlook, Risks, and Covenants
Management commentary is limited to the transaction terms. Key risks and covenants include:
- Redemption Risk: In the event of default, the Company may be required to redeem Notes at a 115% premium.
- Forced Conversion: The Company may force conversion of Notes if the stock price exceeds $2.36 for 10 consecutive trading days with sufficient volume.
- Issuance Restrictions: The Company is restricted from issuing equity below the $1.18 conversion price for 18 months post-closing.
- Standstill Agreement: PharmaCyte agreed to a standstill on acquiring additional securities for 12 months after the investor board seat falls away.
- Registration Rights: The Company must file a resale registration statement within 30 days of closing.
Investor Verification Checklist
- Verify the closing of the $6.85 million private placement on or around November 17, 2023.
- Confirm the appointment of Joshua Silverman to the Board of Directors.
- Monitor the filing of the resale registration statement required within 30 days of closing.
- Review the full text of the Collaboration Agreement to understand the scope of the joint research with PharmaCyte.
- Assess the impact of the 18-month pricing restriction on future capital raising efforts.